MicroRNA signatures in tumor tissue related to angiogenesis in non-small cell lung cancer

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Donnem, Tom ^a,b   Fenton, Christopher G ^b   Lonvik, Kenneth ^a,b   Berg, Thomas ^a,b   Eklo, Katrine ^a,b   Andersen, Sigve ^a,b   Stenvold, Helge ^a,b   Al Shibli, Khalid ^c   Al Saad, Samer ^a,b   Bremnes, Roy M ^a,b   Busund, Lill Tove ^a,b  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c NORDLAND HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MIRN155 MICRORNA, HUMAN; TRANSCRIPTOME; TUMOR MARKER;

ARTICLE; CANCER SPECIFIC SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; REAL TIME POLYMERASE CHAIN REACTION; RNA ANALYSIS; TUMOR VASCULARIZATION; UPREGULATION; VALIDATION PROCESS; AGED; COHORT ANALYSIS; FEMALE; GENETICS; LUNG TUMOR; MALE; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; POLYMERASE CHAIN REACTION; REPRODUCIBILITY; VASCULARIZATION;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84856247990     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029671     Document Type: Article

References (61)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225-49.
2. Lebanony D, Benjamin H, Gilad S, Ezagouri M, Dov A, et al. (2009) Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol 27: 2030-7.
3. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, et al. (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542-50.
4. Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, et al. (2009) The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 14: 253-63.
5. Lin PY, Yu SL, Yang PC, (2010) MicroRNA in lung cancer. Br J Cancer 103: 1144-8.
6. Esquela-Kerscher A, Slack FJ, (2006) Oncomirs- microRNAs with a role in cancer. Nat Rev Cancer 6: 259-69.
7. Krol J, Loedige I, Filipowicz W, (2010) The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 11: 597-610.
8. Wu X, Piper-Hunter MG, Crawford M, Nuovo GJ, Marsh CB, et al. (2009) MicroRNAs in the pathogenesis of Lung Cancer. J Thorac Oncol 4: 1028-34.
9. Cho WC, (2010) MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol 42: 1273-81.
10. Jiang L, Huang Q, Zhang S, Zhang Q, Chang J, et al. (2010) Hsa-miR-125a-3p and hsa-miR-125a-5p are downregulated in non-small cell lung cancer and have inverse effects on invasion and migration of lung cancer cells. BMC Cancer 10: 318.
11. Sun Y, Bai Y, Zhang F, Wang Y, Guo Y, et al. (2010) miR-126 inhibits non-small cell lung cancer cells proliferation by targeting EGFL7. Biochem Biophys Res Commun 391: 1483-9.
12. Cho WC, (2009) Role of miRNAs in lung cancer. Expert Rev Mol Diagn 9: 773-6.
13. Bishop JA, Benjamin H, Cholakh H, Chajut A, Clark DP, et al. (2010) Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach. Clin Cancer Res 16: 610-9.
14. Hu Z, Chen X, Zhao Y, Tian T, Jin G, et al. (2010) Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 28: 1721-6.
15. Landi MT, Zhao Y, Rotunno M, Koshiol J, Liu H, et al. (2010) MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res 16: 430-41.
16. Patnaik SK, Kannisto E, Knudsen S, Yendamuri S, (2010) Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection. Cancer Res 70: 36-45.
17. Raponi M, Dossey L, Jatkoe T, Wu X, Chen G, et al. (2009) MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res 69: 5776-83.
18. Seike M, Goto A, Okano T, Bowman ED, Schetter AJ, et al. (2009) MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci U S A 106: 12085-90.
19. Voortman J, Goto A, Mendiboure J, Sohn JJ, Schetter AJ, et al. (2010) MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res 70: 8288-98.
20. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, et al. (2006) Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9: 189-98.
21. Du L, Pertsemlidis, (2010) microRNAs and lung cancer: tumors and 22-mers. Cancer Metastasis Rev 29: 109-22.
22. Kulshreshtha R, Davuluri RV, Calin GA, Ivan M, (2008) A microRNA component of the hypoxic response. Cell Death Differ 15: 667-71.
23. Olson P, Lu J, Zhang H, Shai A, Chun MG, et al. (2009) MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev 23: 2152-65.
24. Suarez Y, Sessa WC, (2009) MicroRNAs as novel regulators of angiogenesis. Circ Res 104: 442-54.
25. Hanahan D, Weinberg RA, (2000) The hallmarks of cancer. Cell 100: 57-70.
26. Nguewa PA, Calvo A, Pullamsetti SS, Banat GA, Grimminger F, et al. (2011) Tyrosine kinase inhibitors with antiangiogenic properties for the treatment of non-small cell lung cancer. Expert Opin Investig Drugs 20: 61-74.
27. Kuehbacher A, Urbich C, Zeiher AM, Dimmeler S, (2007) Role of Dicer and Drosha for endothelial microRNA expression and angiogenesis. Circ Res 101: 59-68.
28. Andersen S, Donnem T, Al-Saad S, Al-Shibli K, Busund LT, et al. (2009) Angiogenic markers show high prognostic impact on survival in marginally operable non-small cell lung cancer patients treated with adjuvant radiotherapy. J Thorac Oncol 4: 463-71.
29. Andersen S, Eilertsen M, Donnem T, Al-Saad S, Al-Shibli K, et al. (2011) Diverging prognostic impacts of hypoxic markers according to NSCLC histology. Lung Cancer 72: 294-302.
30. Donnem T, Al-Saad S, Al-Shibli K, Delghandi MP, Persson M, et al. (2007) Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non small cell lung cancer. Clin Cancer Res 13: 6649-57.
31. Donnem T, Al-Saad S, Al-Shibli K, Andersen S, Busund LT, et al. (2008) Prognostic impact of platelet-derived growth factors in non-small cell lung cancer tumor and stromal cells. J Thorac Oncol 3: 963-70.
32. Donnem T, Al-Shibli K, Al-Saad S, Delghandi MP, Busund LT, et al. (2009) VEGF-A and VEGFR-3 correlate with nodal status in operable non-small cell lung cancer: inverse correlation between expression in tumor and stromal cells. Lung Cancer 63: 277-83.
33. Donnem T, Al-Shibli K, Al-Saad S, Busund LT, Bremnes RM, (2009) Prognostic impact of fibroblast growth factor 2 in non-small cell lung cancer: coexpression with VEGFR-3 and PDGF-B predicts poor survival. J Thorac Oncol 4: 578-85.
34. Donnem T, Andersen S, Al-Shibli K, Al-Saad S, Busund LT, et al. (2010) Prognostic impact of Notch ligands and receptors in nonsmall cell lung cancer: Coexpression of Notch-1 and vascular endothelial growth factor-A predicts poor survival. Cancer 116: 5676-85.
35. Donnem T, Al-Shibli K, Andersen S, Al-Saad S, Busund LT, et al. (2010) Combination of low vascular endothelial growth factor A (VEGF-A)/VEGF receptor 2 expression and high lymphocyte infiltration is a strong and independent favorable prognostic factor in patients with nonsmall cell lung cancer. Cancer 116: 4318-25.
36. Donnem T, Al-Saad S, Al-Shibli K, Busund LT, Bremnes RM, (2010) Co-expression of PDGF-B and VEGFR-3 strongly correlates with lymph node metastasis and poor survival in non-small-cell lung cancer. Ann Oncol 21: 223-31.
37. Donnem T, Eklo K, Berg T, Sorbye SW, Lonvik K, et al. (2011) Prognostic Impact of MiR-155 in Non-Small Cell Lung Cancer Evaluated by in Situ Hybridization. J Transl Med 9: 6.
38. Donnem T, Lonvik K, Eklo K, Berg T, Sorbye SW, et al. (2011) Independent and tissue-specific prognostic impact of miR-126 in nonsmall cell lung cancer: Coexpression with vascular endothelial growth factor-A predicts poor survival. Cancer 15: 3193-200.
39. Kuehbacher A, Urbich C, Dimmeler S, (2008) Targeting microRNA expression to regulate angiogenesis. Trends Pharmacol Sci 29: 12-5.
40. Kulshreshtha R, Ferracin M, Wojcik SE, Garzon R, Alder H, et al. (2007) A microRNA signature of hypoxia. Mol Cell Biol 27: 1859-67.
41. Wu F, Yang Z, Li G, (2009) Role of specific microRNAs for endothelial function and angiogenesis. Biochem Biophys Res Commun 386: 549-53.
42. Zhang C, (2010) MicroRNAs in vascular biology and vascular disease. J Cardiovasc Transl Res 3: 235-40.
43. Meister J, Schmidt MH, (2010) miR-126 and miR-126*: new players in cancer. ScientificWorldJournal 10: 2090-100.
44. Wang S, Aurora AB, Johnson BA, Qi X, McAnally L, et al. (2008) The endothelial specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell 15: 261-271.
45. Nikolic I, Plate KH, Schmidt MH, (2010) EGFL7 meets miRNA-126: an agiogenesis alliance. J Angiogenesis Res 2: 9.
46. Faraoni I, Antonetti FR, Cardone J, Bonmassar E, (2009) miR-155 gene a typical multifunctional microRNA. Biochim Biophys Acta 1792: 497-505.
47. Liu LZ, Li C, Chen Q, Jing Y, Carpenter R, et al. (2011) MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1α expression. PLoS ONE 22: e19139.
48. Al-Saad S, Al-Shibli K, Donnem T, Al-Shibli K, Persson M, et al. (2009) Diverse prognostic roles of Akt isoforms, PTEN and PI3K in tumor epithelial cells and stromal compartment in non-small cell lung cancer. Anticancer Res 29: 4175-83.
49. Ghosh G, Subramanian IV, Adhikari N, Zhang X, Joshi HP, et al. (2010) Hypoxia-induced microRNA-424 expression in human endothelial cells regulates HIF-α isoforms and promotes angiogenesis. J Clin Invest 120: 4141-54.
50. Nakashima T, Jinnin M, Etoh T, Fukushima S, Masuguchi S, et al. (2010) Down-regulation of mir-424 contributes to the abnormal angiogenesis via MEK1 and cyclin E1 in senile hemangioma: its implications to therapy. PLoS ONE 5: e14334.
51. Devlin C, Greco S, Martelli F, Ivan M, (2011) miR-210: More than a silent player in hypoxia. IUBMB Life 63: 94-100.
52. Puissêgur MP, Mazure NM, Bertero T, (2011) miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity. Cell Death Differ 18: 465-78.
53. Zhou W, Feng X, Wu Y, Benge J, Zhang Z, et al. (2009) FGF-receptor substrate 2 functions as a molecular sensor integrating external regulatory signals into the FGF pathway. Cell Res 19: 1165-77.
54. World Health Organization (1999) Histological Typing of Lung and Pleural Tumours. 3 edn Geneva, Switzerland Springer-Verlag.
55. Goldstraw P, (2009) The 7th Edition of TNM in Lung Cancer: what now? J Thorac Oncol 4: 671-3.
56. Ritchie ME, Silver J, Oshlack A, Holmes M, Diyagama D, et al. (2007) A comparison of background correction methods for two-colour microarrays. Bioinformatics 23: 2700-7.
57. Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, et al. (2001) Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet 29: 365-71.
58. Wettenhall JM, Smyth GK, (2004) limmaGUI: a graphical user interface for linear modeling of microarray data. Bioinformatics 20: 3705-6.
59. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I, (2001) Controlling the false discovery rate in behavior genetics research. Behav Brain Res 125: 279-84.
60. Gidskehaug l, Stodkilde-Jorgensen H, Martens M, Martens H, (2004) Bridge-PLS regression:two-block bilinear regression without deflation. Journal of Chemometrics 18: 208-15.
61. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545-50.